Citius Oncology develops and commercializes targeted immune therapies, exemplified by LYMPHIR™ (denileukin diftitox-cxdl), which is FDA-approved for treating relapsed or refractory cutaneous T-cell lymphoma (CTCL). The company focuses on reducing clinical risks and expediting development pathways for oncology treatments through its proprietary technology and regulatory protections.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatment options for relapsed or refractory cutaneous T-cell lymphoma (CTCL) have limitations, and there remains a need for targeted therapies that can improve patient outcomes. Developing and commercializing new oncology treatments can be a lengthy and risky process.
Solution
Citius Oncology is a biopharmaceutical company focused on developing and commercializing targeted immune therapies for cancer. Their lead product, LYMPHIR™ (denileukin diftitox-cxdl), is FDA-approved for the treatment of relapsed or refractory CTCL. The company aims to reduce clinical risks and expedite development pathways for oncology treatments through its proprietary technology and regulatory protections.
Target Audience
The primary target audience includes patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL) and the healthcare professionals who treat them.
Features
- LYMPHIR™ (denileukin diftitox-cxdl): A targeted immune therapy approved by the FDA for relapsed or refractory CTCL.
- Focus on treatments with reduced development and clinical risks.
- Intellectual property and regulatory exclusivity protections.